Tekla Life Sciences Investors

Tekla Life Sciences Investors

HQLยทNYSE

$16.93

-1.5%
Financial ServicesAsset Management

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

At a Glance

Live Snapshot
Market Cap$514.81M
EPS2.9600
P/E Ratio5.72
Earnings Date06/24/2025
HQL

Tekla Life Sciences Investors Cash Conversion Engine

HQL ยท NYSE
Net Income85.59M
Depreciation & Amortization0.00
Stock-Based Compensation0.00
Change in Working Capital-203.41K
Others-87.71M
Capital Expenditures-5.00
Free Cash Flow-2.32M

Cash Flow Quality Analysis

FCF Conversion Rate

-2.7%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

-0.0%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

Working Capital Impact

-$203.41K

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.

Tekla Life Sciences Investors Cash Flow Statement

HQL โ€ข NYSE

Tekla Life Sciences Investors Cash Flow StatementSep 2025Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009Sep 2008Sep 2007Sep 2006Sep 2005
OPERATING ACTIVITIES
85.6M
22.4M
-104.6K
64.5K
123.1K
-70.5K
28.7K
68.6K
-11.9K
40.5K
89.3K
84.6K
77.6M
37.5M
10.2M
-21.7M
60.3M
50.5M
-21.4M
44.8M
-87.7M
-22.4M
104.6K
-64.5K
-123.1K
70.5K
-28.7K
-68.6K
11.9K
-40.5K
-141.8K
-76.1K
-56.5M
-37.5M
-10.2M
21.7M
-60.3M
-50.5M
21.4M
-44.8M
-203.4K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-65.0
948.0
-24.8K
118.3M
1.9M
13M
11.8M
-3.7M
-2.1M
-3.2M
-2.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-52.6K
9.5K
21.1M
118.3M
1.9M
13M
11.8M
-3.7M
-2.1M
-3.2M
INVESTING ACTIVITIES
-314.1M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
339.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
14.3M
-58.2M
9.8M
(25.2M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(14.3M)
-58.2M
(9.8M)
FINANCING ACTIVITIES
-31.6M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-14K
-9.4K
-10.2M
-11.2M
-3.6M
-7.6M
-11.8M
-10.6M
-11.1M
-7.3M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-10.9M
-107.1M
-3.8M
(0.0)
(0.0)
(0.0)
(71.4M)
(0.0)
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
66.5K
0.0
-10.9M
-107.1M
-3.7M
0.0
0.0
0.0
71.4M
0.0
-31.6M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
52.5K
-9.4K
-21.1M
-118.3M
-7.3M
-7.6M
-11.8M
-10.6M
60.3M
-7.3M
CASH FLOW SUMMARY
8.8M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
75.5K
32.0
-545.0
0.0
0.0
1.1M
0.0
0.0
0.0
0.0
-34.0
35.0
117.0
0.0
-5.4M
5.4M
0.0
0.0
0.0
-700K
0.0
445.0
990.0
1.1M
1.1M
41.0
0.0
0.0
0.0
2.0
36.0
0.0
572.0
0.0
5.5M
100K
0.0
0.0
0.0
700K
75.5K
477.0
445.0
0.0
1.1M
1.1M
0.0
0.0
0.0
2.0
2.0
36.0
689.0
0.0
100K
5.5M
0.0
0.0
0.0
0.0
-2.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-52.6K
9.5K
21.1M
118.3M
1.9M
13M
11.8M
-3.7M
-2.1M
-3.2M

SEC Filings

HQL - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2024

N/A

April 22, 2024
June 25, 2024
2024
8-K

8-K 2023

N/A

September 12, 2023
September 06, 2023
2023
DEF 14A

DEF 14A 2023

N/A

April 11, 2023
June 08, 2023
2023
DEF 14A

DEF 14A 2022

N/A

April 12, 2022
June 09, 2022
2022
DEF 14A

DEF 14A 2019

N/A

April 15, 2019
June 13, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 18, 2018
June 14, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 18, 2017
June 15, 2017
2017
DEF 14A

DEF 14A 2014

N/A

April 30, 2014
June 09, 2014
2014
DEF 14A

DEF 14A 2013

N/A

April 25, 2013
June 04, 2013
2013
8-K

8-K 2013

N/A

March 25, 2013
March 22, 2013
2013
Showing 1 to 10 of 21 filings